ArticleClinics (Sao Paulo, Brazil)2026
Lactate dehydrogenase-to-Albumin Ratio (LAR) predicts mortality in critically ill patients with hypertensive heart failure: A MIMIC-IV database analysis.
Article in Clinics (Sao Paulo, Brazil), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Association between lactate dehydrogenase-to-albumin ratio and short-term mortality in critically ill patients with urosepsis: evidence from dual retrospective cohorts.Frontiers in cellular and infection microbiology · 2026Article
- The lactate dehydrogenase-to-albumin ratio is independently associated with moderate-to-severe tubulointerstitial fibrosis in patients with IgA nephropathy.Frontiers in nephrology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHypertensive heart disease with heart failure is a severe cardiovascular condition with high mortality rates. The relationship between the Lactate Dehydrogenase to Albumin Ratio (LAR) and mortality in these patients remains unclear.
methodsThe authors analyzed 3019 patients with hypertensive heart failure using data from the MIMIC-IV database. Cox regression models were used to assess the association between LAR and mortality, with adjustments for various covariates. Restricted cubic spline analysis was employed to evaluate the threshold effect of LAR on mortality. Kaplan-Meier survival curves and subgroup analyses further explored the impact of LAR.
resultsLAR was significantly associated with increased mortality across all time points: hospital mortality (HR = 4.86, 95% CI 4.12 to 5.73; p < 0.001), 30-day mortality (HR = 4.16, 95% CI 3.56 to 4.87; p < 0.001), 90-day mortality (HR = 3.56, 95% CI 3.08 to 4.12; p < 0.001), and 365-day mortality (HR = 2.91, 95% CI 2.54 to 3.33; p < 0.001). These associations remained significant after multivariable adjustments. The Cox regression model with restricted cubic spline analysis revealed a threshold effect of LAR on mortality, with turning points at 1.662 for hospital mortality, 2.393 for 30-day mortality, 2.407 for 90-day mortality, and 2.406 for 365-day mortality (all p < 0.001 for non-linear tests). Kaplan-Meier survival curves showed significant differences in survival across LAR quartiles for all mortality outcomes (all p < 0.001).
conclusionThe LAR is significantly associated with mortality in critically ill patients, with a clear threshold effect. LAR may serve as a potential prognostic marker for identifying high-risk patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.